Belgium biopharmaceutical company Ablynx has appointed Dr Robert Zeldin to replace Dr Dominique Tersago as its chief medical officer.
A clinical immunologist, Zeldin has more than 15 years combined regulatory and industry experience, having previously served at Merck & Co, Novartis and the FDA.
He has held senior level clinical development positions within pharma and prior to his move into the industry, Zeldin spent several years in private practice and two years as a medical officer at the FDA’s Center for Biologics Evaluation and Research.
Ablynx CEO Dr Edwin Moses said: “We are very pleased that someone with Robert’s track record and experience is joining Ablynx as chief medical officer.
“Partly based in the USA, he will be invaluable in supporting our global clinical development activities as well as our interactions with the regulatory agencies and other key stakeholders.”